Day 1: Tuesday 7th February 2017

08:30

Registration and refreshments

09:00

Welcome

Mr Nicholas Cappuccino
09:05

Chairman’s opening remarks

Mr Nicholas Cappuccino, Vice-President, Head of Quality and Scientific Affairs, Dr Reddy's Laboratories
Mr Adrian Thomas
09:10

Making medicines accessible and affordable from a sustainability of innovation perspective:

Mr Adrian Thomas, Vice President of Health Economics and Market Access, Janssen Biologics U.S.A.
Mr Nicholas Cappuccino
09:30

Global Quality and Compliance: Threats and Opportunities for Increased Access to Medicines

Mr Nicholas Cappuccino, Vice-President, Head of Quality and Scientific Affairs, Dr Reddy's Laboratories
Dr Eli Gajraj
10:00

Using a HTA process to control the cost of medications

Dr Eli Gajraj, Senior Technical Adviser, National Institute for Health and Care Excellence
10:30

Speed networking

11:30

Roundtable 1: IP strategy (Generics)

Mr Imre Ravadits, Head of I.P., Egis Pharmaceuticals
11:30

Roundtable 2: Innovative clinical research strategies (Generics)

Mrs Diana Foster, CEO, Total Clinical Trial Management
11:30

Roundtable 3: Pricing, reimbursement and market access (Biosimilars)

Mr Adam Levysohn, Head of Global Market Access Biogen Biosimilars Business Unit, Biogen
11:30

Roundtable 4: Biosimilars vs Biobetters: What’s the Better Value Driver?

Ms Jennifer Smith-Parker, Deputy Editor, EMEA, BioPharm Insight
12:20

Lunch

Generic industry strategy
13:35

Intro: Generic industry strategy

Mr Nicholas Cappuccino, Vice-President, Head of Quality and Scientific Affairs, Dr Reddy's Laboratories
Biosimilar industry strategy
13:35

Intro: Biosimilar industry strategy

Dr Karsten Roth, Director Clinical Operations, Cinfa Biotech
Generic industry strategy
13:40

Spanish Generics Market 2017: Challenges and Opportunities?

Mr Joaquin Rodrigo, General Director, Sandoz
Biosimilar industry strategy
13:40

The last hurdle: Management and strategies for preparing a biosimilar dossier

Session led by: asphalion,-s.l.
Generic industry strategy
14:00

Significant differences in enrolment related generic markets and success stories related to patient recruitment

Mrs Diana Foster, CEO, Total Clinical Trial Management
Biosimilar industry strategy
14:00

Review of global approvals for biosimilars – what can we learn?

Mrs Jane Hippenmeyer, Scientific Affairs Director, Amgen
Generic industry strategy
14:20

Increasing generics efficiency and explore new business opportunities (US/Global)

Mr Gopalakrishnan Venkatesan, Vice President of Business Development, Wockhardt Llc
Biosimilar industry strategy
14:20

From biosimilars to biogenerics – the way to lower treatment costs?

Dr Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Generic industry strategy
14:40

How must the industry adapt to the changing commercial policies environment?

Mr Luis Magarzo Bello, Commercial Excellence Head, Mylan
Biosimilar industry strategy
14:40

Key success factors in biosimilars development (technical and clinical aspects)

Mr Klaus Martin, Chief Scientific Officer, Polpharma Biologics
Generic industry strategy
15:00

Q&A with session speakers

Biosimilar industry strategy
15:00

Q&A with session speakers

15:15

Afternoon refreshments and exhibition viewing

Market Access for Affordable Medicine
15:55

Intro: Market Access for Affordable Medicine

Mr Gopalakrishnan Venkatesan, Vice President of Business Development, Wockhardt Llc
Biosimilar development challenges
15:55

Intro: Biosimilar development challenges

Mr Klaus Martin, Chief Scientific Officer, Polpharma Biologics
Market Access for Affordable Medicine
16:00

Adding value through the API

Dr Roger Viney, Senior Director, Off Patent API, Hovione FarmaCiencia SA
Biosimilar development challenges
16:00

How to design the right clinical development programme for biosimilars ?

Dr Karsten Roth, Director Clinical Operations, Cinfa Biotech
Market Access for Affordable Medicine
16:20

Trends in pricing and profits

Frances Cloud, Founder, Pharmacloud Ltd
Biosimilar development challenges
16:20

Improving patient access to treatment in the age of biosimilars: Realizing the promise

Mr Samir Desai, Sr. Vice President & SBU Head, Zydus Cadila Healthcare Ltd.
Market Access for Affordable Medicine
16:40

Policy Influence on National Market Entry and Access in the Pharmaceutical Industry

Mr David Jauch, Global Regulatory Affairs and Government Relations Manager, Fresenius Kabi
Biosimilar development challenges
16:40

Challenges for biosimilars: Addressing the immunogenicity issues for biosimilars

Mr Mourad Farouk Rezk, Senior Director and Global Head of Medical Affairs, Biogen
Generic industry strategy
17:00

Q&A with session speakers

Biosimilar industry strategy
17:00

Q&A with session speakers

17:30

Networking drinks reception

last published: 03/Feb/17 14:45 GMT
BOOK NOW